Stifel Nicolaus Raises Knight Therapeutics (TSE:GUD) Price Target to C$7.45

Knight Therapeutics (TSE:GUD) had its target price boosted by Stifel Nicolaus from C$6.25 to C$7.45 in a research report issued to clients and investors on Tuesday,BayStreet.CA reports. The brokerage presently has a “buy” rating on the stock. Stifel Nicolaus’ price objective would suggest a potential upside of 23.34% from the company’s previous close.

Several other brokerages also recently commented on GUD. Canaccord Genuity Group downgraded shares of Knight Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, March 21st. Research Capitl upgraded shares of Knight Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Tuesday, March 11th. One equities research analyst has rated the stock with a hold rating, one has issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of C$7.48.

Knight Therapeutics Stock Performance

Shares of Knight Therapeutics stock opened at C$6.04 on Tuesday. The company has a market cap of C$610.95 million, a P/E ratio of -20.16, a PEG ratio of -1,013.50 and a beta of 0.50. The company has a current ratio of 3.36, a quick ratio of 1.79 and a debt-to-equity ratio of 7.52. The business has a 50-day moving average price of C$5.72 and a two-hundred day moving average price of C$5.59. Knight Therapeutics has a 1-year low of C$5.09 and a 1-year high of C$6.45.

Insider Transactions at Knight Therapeutics

In other Knight Therapeutics news, insider Sime Armoyan bought 17,600 shares of the firm’s stock in a transaction dated Tuesday, March 4th. The stock was purchased at an average cost of C$5.48 per share, with a total value of C$96,488.48. Insiders sold a total of 3,143,300 shares of company stock valued at $19,733,740 over the last ninety days. 45.62% of the stock is currently owned by insiders.

Knight Therapeutics Company Profile

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.